Vgenomics Secures Seed Funding for Biotech Advancements
- ByStartupStory | January 16, 2024
Biotechnology and healthcare startup Vgenomics India has successfully concluded its seed investment round, with Mumbai Angels and O2 Angel Network leading the way. The investment round also saw the active participation of renowned Angel investors including Rohit Chanana and Sabine Kapasi. Mumbai Angels, now a part of 360 ONE, has expanded its portfolio with this strategic investment in Vgenomics, marking a significant advancement in the field.
The seed funding will play a pivotal role in Vgenomics’ mission to develop diagnostics solutions and scale its existing business with a focus on neonatologists, gynecologists, pediatricians, and clinical geneticists.
This funding round not only validates their innovative approach but also sets the stage for the accelerated development and deployment of solutions aimed at addressing the needs of the staggering 175 million children worldwide affected by rare diseases.
Vgenomics utilizes next-generation sequencing technologies combined with genomics and artificial intelligence to create diagnostics and therapeutics for rare diseases affecting children. These diseases, present at birth and often caused by DNA alterations, pose a significant challenge to global healthcare. By harnessing cutting-edge technologies, Vgenomics aims to bring novel solutions to the market, making a substantial impact on the lives of millions of children.
Nandini Mansinghka, CEO of Mumbai Angels, expressed her admiration for Vgenomics’ groundbreaking approach. She stated, “Vgenomics’ groundbreaking approach to harnessing next-generation, AI-powered sequencing technologies to address rare diseases is commendable. We believe this investment not only validates their innovative strategy but also propels the journey towards impacting the lives of millions of children affected by rare diseases worldwide.”
Follow Startup Story
Related Posts
